logo
When eye twitching doesn't stop: Understanding facial muscle spasm and treatments available

When eye twitching doesn't stop: Understanding facial muscle spasm and treatments available

Straits Times13-05-2025

A subtle eye twitch could be the first sign of hemifacial spasm which can spread to the rest of your face. PHOTO: GETTY IMAGES
BRANDED CONTENT When eye twitching doesn't stop: Understanding facial muscle spasm and treatments available A persistent eye twitch may be an early sign of hemifacial spasm, a progressive neurological condition. Specialist neurosurgeon Dr Nicolas Kon explains how timely treatment can halt its progression
Most of us have experienced an occasional eye twitch – often stress-related and fleeting. But when that persistent eye twitching becomes frequent or spreads across the face, it could signal hemifacial spasm (HFS), or facial muscle spasm, a neurological condition that is marked by involuntary muscle contractions on one side of the face.
Dr Nicolas Kon, a hemifacial spasm specialist at Neuro Asia Care, explains: 'The spasms typically begin around the eye and may extend to the cheek, mouth and jaw. In most cases, it is caused by a blood vessel pressing against the root of the facial nerve, disrupting its function.
'As the protective layer of the nerve wears down from this constant contact, abnormal signals are sent to facial muscles which trigger the involuntary twitching and spasms patients experience.'
There are two types of spasms: clonic spasms are fast, repetitive twitches, while tonic spasms cause prolonged tightness in the facial muscles. 'Although brief, these episodes can occur frequently and interfere with daily life,' adds Dr Kon.
Hemifacial spasm affects about 15 in 100,000 people and is seen more often in Asian populations. INFOGRAPHIC: NEURO ASIA CARE
Beyond the physical discomfort, HFS can impact daily life significantly. Activities like reading, driving, or watching TV may become difficult when the eye closes involuntarily. Over time, the unpredictability and visibility of the spams can erode one's confidence, interfere with work and social interactions, contributing to a reduced quality of life, explains Dr Kon.
Diagnosing hemifacial spasm
A persistent, one-sided eye twitch is often the first sign of HFS. If the eye twitch begins to spread or intensify, evaluation by an HFS specialist is recommended. Diagnosis typically includes a physical exam followed by a specialised magnetic resonance imaging or MRI scan to assess whether a blood vessel is compressing the facial nerve and to rule out other conditions such as tumours.
Studies show that hemifacial spasm affects about 15 out of every 100,000 people, and appears to be more common among Asian populations. According to Dr Kon, there is no official data for Singapore, but the numbers are likely to be similar. Many cases may go undiagnosed especially when the milder symptoms are dismissed as fatigue or stress.
'Women, especially those in their 40s to 60s, are more commonly affected, with a higher frequency of symptoms occurring on the left side of the face. These demographic patterns underscore the need for awareness and tailored treatment approaches in our region,' adds Dr Kon.
Treating hemifacial spasms with microvascular decompression
There are three primary treatments for HFS:
Oral medication , which may provide temporary relief in early stages but often loses effectiveness over time.
, which may provide temporary relief in early stages but often loses effectiveness over time. Botulinum toxin injections , which provide temporary relief by relaxing the affected muscles, but need to be repeated every few months.
, which provide temporary relief by relaxing the affected muscles, but need to be repeated every few months. Microvascular decompression (MVD), a one-time procedure that addresses the root cause and offers long-term relief.
'MVD offers a long-term solution for HFS as the procedure directly addresses the root cause – the pressure on the facial nerve,' says Dr Kon.
Performed under general anaesthesia, MVD involves making a small incision behind the ear to access the affected area. A cushion-like pad is then accurately placed between the facial nerve and the compressing blood vessel.
'This accurate placement and repositioning help alleviate the pressure that triggers the facial spasms,' Dr Kon explains.
Patients can choose from three treatment options, depending on their condition and what best fits their lifestyle. INFOGRAPHIC: NEURO ASIA CARE
According to Dr Kon, this is a minimally invasive procedure and most patients stay in hospital for only a few days. Recovery typically involves avoiding strenuous activities like heavy lifting for a month, but patients tend to notice an immediate improvement.
'In my practice, 90 per cent of patients achieve complete relief after MVD surgery. Many patients become spasm-free immediately after surgery. In more severe cases, spasms may take up to several weeks to subside,' says Dr Kon.
Although risks like temporary facial weakness or hearing loss exist, these are uncommon, and quality of life improves significantly, adds Dr Kon.
Dr Kon notes that most of his patients experience complete relief after undergoing MVD surgery. INFOGRAPHIC: NEURO ASIA CARE
MVD is a one-time procedure for most, and is recommended for patients with clear signs of nerve compression, good overall health and symptoms that persist despite other treatments.
MVD may not be suitable for everyone – especially those with mild symptoms or who are medically unfit.
'A personalised approach is essential,' says Dr Kon. 'Whether your goal is symptom relief, reducing eye strain and discomfort, or feeling more confident in social settings, the treatment plan should align with your lifestyle and medical needs.'
To learn more about hemifacial spasm, MVD procedure or consult with Dr Nicolas Kon, visit the Neuro Asia Care website.
Join ST's WhatsApp Channel and get the latest news and must-reads.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Add to cart: The best beauty products to shop this June 2025
Add to cart: The best beauty products to shop this June 2025

Vogue Singapore

time3 days ago

  • Vogue Singapore

Add to cart: The best beauty products to shop this June 2025

Courtesy of Shu Uemura 1 / 5 Shu Uemura Ultime8∞ Sublime Beauty Cleansing Oil Shu Uemura is the go-to brand for make-up and skincare tailored to Asian skin. If you're choosing from their five signature cleansing oils, the one worth incorporating into your routine is the Ultime8∞ Sublime Beauty Cleansing Oil. A sensorial experience rooted in Japanese skincare tradition, it is infused with precious tsubaki oil sourced from handpicked seeds on Japan's Toshima Island. Three pumps of this dissolve even the most stubborn waterproof make-up, all while deeply nourishing the skin. Beyond removing make-up, it neither strips moisture nor leaves behind a greasy film; instead, your complexion feels smooth, supple, and comforted, as if you've just had a facial. — Raushana Salim, beauty intern Shu Uemura Ultime8∞ Sublime Beauty Cleansing Oil, $188, available at Sephora Courtesy of Chanel Beauty 2 / 5 Chanel Éclat Premier Bright Milky Essence Never underestimate the powers of ylang-ylang, at least that's what I'm reminded of whilst gently tapping this milky essence into my skin. Heralded as a premier flower extract by Chanel, the key ingredient emits a soothing scent and has also been proven to improve skin radiance. Coupled with pure niacinamide, a few drops of this lightweight number has been the latest step in my skincare routine. The result has been a brighter and more balanced complexion, given that the product is targeted towards dark spots that can arise from acne or external environmental stressors. — Janice Sim, digital editor Chanel Éclat Premier Bright Milky Essence, $180, available at Chanel Courtesy of Sephora 3 / 5 Pixi Beauty Lip Tone Gloss The Pixi Beauty Lip Tone Gloss is the kind of no-fuss, feel-good product you find yourself reaching for every day. This pH-reactive gloss glides on clear and adjusts to your lips' unique chemistry, leaving behind a subtle flush of colour that breathes life into your lips. It goes one step beyond 'your lips but better,' enhancing your natural lip tone while providing lasting hydration and nourishment—it transforms your lips for the better. Glossed lips may appear hydrated, but many formulas feel sticky and fade quickly. What sets the Lip Tone Gloss apart is its infusion of rosehip seed oil, mango butter, and shea butter, delivering genuine hydration in a non-sticky formula that lasts for hours. It works so well, you'll wonder how it isn't a luxury purchase. A swipe is all it takes to achieve an effortless, polished look. — Raushana Salim, beauty intern Pixi Beauty Lip Tone Gloss, $13, available at Sephora Courtesy of Haus Labs 4 / 5 Haus Labs by Lady Gaga Colour Fuse Blush Powder My blush era is on the up and up. The latest to enter my periphery of vision: Haus Labs's Colour Fuse Blush Powder. Talc-free and packed with anti-inflammatory and moisturising ingredients such as squalane, fermented arnica and hydraberry, this pressed powder harnesses its pigment with care. My personal colour pick is Fire Moon, a warm rush of sunset that feels just right for the summer. It's become my latest obsession; a tap and swipe grants a sheer, audible wash of colour with a satin finish, one that I enjoy slowly building up and painting both my cheeks and peepers in. — Azrin Tan, senior digital writer Haus Labs by Lady Gaga Colour Fuse Blush Powder, $50, available at Sephora Courtesy of Sephora 5 / 5 Virute Labs Damage Reverse Serum If there's a haircare must-have for me, it's a multitasking heat protectant that doubles as a serum—especially with the daily blow-dry torture my hair endures after every wash. Virtue Lab's Damage Reverse Serum, comes through with its Alpha Keratin 60ku® formula. Upon massaging it into the scalp, pleasure is gleaned from its soothing honey scent, whilst its creamy, weightless texture seamlessly melts into the scalp. Post-application, the serum reduces damage, restores lost keratin and strengthens strands from the inside out. — Kashish Malani, digital intern Virute Labs Damage Reverse Serum, $98, available at Sephora

Implants could help treat eye condition which causes vision loss
Implants could help treat eye condition which causes vision loss

Straits Times

time6 days ago

  • Straits Times

Implants could help treat eye condition which causes vision loss

The implant has already received approval from the US Food and Drug Administration. ST PHOTO: DESMOND FOO Implants could help treat eye condition which causes vision loss SINGAPORE - Instead of receiving uncomfortable eye injections around once a month for a disease that can lead to blindness, patients may soon have an easier alternative. A new innovation will allow them to be treated twice a year via an implant the size of a rice grain. Swiss healthcare firm Roche, which developed the treatment, is now conducting a study of the implant involving more than 400 participants in 16 countries, including Singapore – the only country in South-east Asia in the study and one of only three Asian countries. The study, which ends in December 2026, looks at the efficacy and safety of refilling the implant every nine months, compared with every six months. The implant has already received approval from the US Food and Drug Administration. Treating neovascular age-related macular degeneration (nAMD) currently requires injections into the eye as often as once a month. Studies have noted that patients' discomfort with the treatment can lead to undertreatment of the disease. The disease affects the part of the eye that provides the sharp vision needed for activities such as reading and driving, and can result in rapid and severe vision loss if left untreated. It results when new and abnormal blood vessels grow uncontrolled under the macula – the part of the retina responsible for sharp central vision – causing swelling, bleeding and fibrosis. The condition, also known as 'wet' AMD because these new blood vessels leak fluid into the retina, is one of the leading causes of blindness in Singapore, affecting more than 125,000 people aged 40 or older. This number is expected to increase to almost 200,000 by 2040, according to a study published in Annals, the official journal of the Academy of Medicine, Singapore in 2018. Roche's innovation to treat nAMD a refillable eye implant that continuously delivers a customised formulation of ranibizumab – a drug used to treat a number of eye conditions – over a period of several months. Also known as a port delivery system, the implant is inserted into the eye via a simple procedure and requires just two refills a year. Roche said in a statement that the implant could result in more reliable improvements in vision for people living with nAMD, reducing the risk of disease recurrence. Decreasing the need for frequent eye injections and doctor visits can also reduce the treatment burden for patients, the firm said. Singapore currently has four sites involved with the trial – the National University Hospital (NUH), Singapore General Hospital, Tan Tock Seng Hospital, and Eye & Retina Surgeons @ Camden Medical, a private clinic. Prof Caroline Chee and Dr Yuen Yew Sen from the department of ophthalmology at National University Hospital who took part in the trial. ST PHOTO: DESMOND FOO Dr Yuen Yew Sen, a consultant with NUH's ophthalmology department, is among those involved with the Roche's study here. He told The Straits Times only those who have recently been diagnosed with nAMD qualify for the trial, and four patients have received the implant at NUH. Once the treatment becomes commercially available – which he said could happen by 2026 – most patients should qualify for the treatment, except for those who have other eye conditions such as glaucoma. Beyond some initial minor discomfort following the surgery, patients who receive the implant are unlikely to notice it is even there, Dr Yuen said. 'Once the stitches dissolve, they don't actually feel anything,' said Dr Yuen, noting that similar implants are also used to treat conditions such as glaucoma. Such implants can also be used to treat other diseases related to the eyes, with trials looking at their use in addressing diabetic retinopathy on the cards, he said. Professor Gemmy Cheung, head of the retina research group at the Singapore Eye Research Institute, notes that nAMD presents differently in Asian populations due to the higher prevalence of a subtype known as polypoidal choroidal vasculopathy (PCV). 'PCV primarily impacts the blood vessels in the layer beneath the retina, causing serious vision impairment or even vision loss if left untreated,' she said. This is of concern because PCV has historically been considered more difficult to treat, with less predictable outcomes than typical nAMD, she said. While conventional treatments are effective in most PCV cases, frequent retreatment is required, said Prof Cheung, who also heads the medical retina department of the Singapore National Eye Centre. Lapses in treatment can result in reactivation of lesions and new instances of bleeding, she added. New therapies such as the port delivery system offer a 'promising approach to providing sustained disease control' in PCV, she said, adding they can potentially reduce the burden of frequent injections and improve long-term outcomes for patients. Join ST's WhatsApp Channel and get the latest news and must-reads.

Singapore-based Quadria's 3rd healthcare fund closes at US$1.1 billion, above US$800 million target
Singapore-based Quadria's 3rd healthcare fund closes at US$1.1 billion, above US$800 million target

Business Times

time27-05-2025

  • Business Times

Singapore-based Quadria's 3rd healthcare fund closes at US$1.1 billion, above US$800 million target

[SINGAPORE] Quadria Capital, a Singapore-based private equity (PE) firm, announced on Tuesday (May 27) the final close of its third healthcare fund at nearly US$1.1 billion. That is above the original target of US$800 million, said the healthcare-focused company, which manages more than US$4 billion across 27 investments in South and South-east Asia. Its investors – which include North American and European sovereign wealth funds and asset managers – may also commit another US$300 million during the investment phase of the third fund. This could bring the total committed capital to around US$1.3 billion when Quadria fully deploys the fund. The oversubscription comes even as PE firms continue to face challenges in raising capital, Quadria's co-founder and managing partner Abrar Mir told The Business Times. 'This has been one of the most difficult, complex fundraising environments that we've ever witnessed... even worse than the dotcom crisis and the global financial crisis of 2008-09.' According to a McKinsey report, PE fundraising in Asia-Pacific plunged almost 77 per cent to US$61 billion in 2024, from US$263 billion in 2021. That was driven mainly by American institutional investors – the world's largest PE investors – who pulled back from China amid growing bilateral tensions. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Draw of a US$5 trillion market Still, institutional investors outside the US find Asia's US$5 trillion healthcare market appealing, Mir said. 'We're increasingly seeing institutional investors in Asia, who understand the opportunities of Asia becoming much more prominent going forward,' he added. Apart from drawing capital from several Asian sovereign investors, Quadria's fund also secured new commitments from Indian investors, spanning banks, insurers and family offices, he added. Middle-Eastern institutions, including those from Saudi Arabia, the United Arab Emirates and Bahrain, invested into Quadria's fund for the first time as well. Boston Consulting Group forecasts that Asian healthcare is expected to drive 40 per cent of global healthcare growth by 2030. Often viewed as a defensive sector that can withstand the ups and downs of economic cycles, healthcare has been steadily drawing more private investments. According to a Bain report, global PE deal activity in the sector surged last year, to an estimated US$115 billion – the second-highest annual deal value on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. About 40 per cent of Quadria's fund has already been deployed, including in India's eyecare chain Maxivision and Asia's largest dialysis chain NephroPlus. Quadria expects to seal two new investments in South-east Asia soon. The company invests in two types of businesses – the first are those that either manufacture or provide a healthcare service to domestic markets, such as hospitals. The second is in businesses that produce healthcare products in Asia, and sell globally. Mir said that Quadria is also assessing deals in Asia and in the Gulf Cooperation Council region.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store